Following of survey of 99 neurologists done by his firm’s partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly’s (LLY) Emgality is lagging and that Teva’s Ajovy appears to be gaining ground on Amgen’s Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the” lack of clarity regarding when/where EBITDA will hit a trough.” On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals’ (ALDR) eptinezumab “appears to be particularly top-of-mind among migraine specialists.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.